Drug resistance mechanisms in chronic lymphocytic leukemia

Leukemia

Volumn 10, Issue 12, 1996, Pages 1944-1949

  Ribrag, V ^a   Massade, L ^b   Faussat, A M ^c   Dreyfus, F ^c   Bayle, C ^a   Gouyette, A ^b   Marie, J P ^c  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CNRS   (France)

^c HÔTEL DIEU   (France)

Author keywords

CLL; Drug resistance; Glutathione system; MDR; Topoisomerase II

Indexed keywords

CHLORAMBUCIL; CYCLINE; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; GLUTATHIONE; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; ISOENZYME; PREDNISONE; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; ENZYME ACTIVITY; HUMAN; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; PRIORITY JOURNAL;

EID: 0030461580     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219-234.
2. Binet JL, Auquier A, Dighiero C, Chastang C, Piquet H, Goasgen I, Vauguier G, Potron G, Colona P, Oberling F, Thomas M, Tchernia G, Jacquillat C, Boivin P, Lesty C, Duault MT, Mauconduit M, Bellabes S, Gremy F. A new pronostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198-206.
3. Sawitsky A, Rai KR, Glidewell O, Silver RT. Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood 1977; 50: 1049-1059.
4. Galton DAG, Wiltshaw E, Szur L, Davie JV. The use of chlorambucil and steroids in the treatment of chronic lymphocytic leukemia. Br J Haematol 1961; 7: 73-98.
5. Montserrat E, Rozman C. Chronic lymphocytic leukemia: present status. Ann Oncol 1995; 6: 219-235.
6. Catovsky D, Fooks J, Richards S. Prognostic factors in chronic lymphocytic leukemia: the importance of age, sex and response to treatment in survival. Br J Haematol 1989; 72: 141-149.
7. Gottesman MM, Patan I. The multidrug transporter, a double-edge sword. J Biol Chem 1988; 263: 12163-12166.
8. Shustik C, Groulx N, Gros P. Analysis of multidrug resistance (MDR-1) gene expression in chronic lymphocytic leukemia (CLL). Br J Haematol 1991; 79: 50-56.
9. Majumdar G, Singh AK. P-glycoprotein expression in drug-resistant chronic lymphoproliferative disorder. Leuk Lymphoma 1991; 5: 387-390.
10. Wallner J, Gisslinger H, Gisslinger B, Gsur A, Göltz M, Zöchbauer S, Pirker R. MDR1 gene expression in chronic lymphocytic leukemia. Leuk Lymphoma 1994; 13: 333-338.
11. Sonneveld P, Nooter K, Burghouts JTM, Herweijer H, Adriaansen HJ, van Dongen JJM. High expression of the MDR-3 multidrug resistance gene in advanced-stage chronic lymphocytic leukemia. Blood 1992; 79: 1496-1500.
12. Wulf G, Kluding H, Ho AD, Doerner M, Doehner H, Manegold C, Hunstein W. Multidrug resistance phenotype in patients with chronic lymphocytic leukemia as detected by immunofluorescence (FACS) and Northern blot analysis. Leukemia Res 1994; 18: 475-484.
13. Sparrow RL, Hall FJ, Siregard H, Van Der Weyden MB. Common expression of the multidrug resistance marker P-glycoprotein in B-cell chronic lymphocytic leukemia and correlation with in vitro drug resistance. Leukemia Res 1993; 17: 941-947.
14. Grulois I, Fardel O, Drenou B, Lamy T, Le Prisé PY, Fauchet R. Multidrug resistance in B-cell chronic lymphocytic leukemia. Acta Haematol 1995; 94: 78-83.
15. Davies SM, Robson CN, Davies SL, Hickson ID. Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. J Biol Chem 1988; 263: 17724-17729.
16. Webb CD, Latham MD, Lock RB, Sullivan D. Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line. Cancer Res 1991; 51: 6543-6549.
17. Deffie AM, Batra JK, Goldenberg GJ. Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycinsensitive and resistant P388 leukemia cell lines. Cancer Res 1989; 49: 58-62.
18. Potmesil M, Hsiang YH, Liu LF, Bank B, Grossberg H, Kirshenbaum S, Forlenzar TJ, Penziner A, Kanganis D, Knowles D, Traganos D, Traganos F, Silber R. Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. Cancer Res 1988; 48: 3537-3543.
19. McKenna SL, Whittaker JA, Padua RA, Holmes JA. Topoisomerase II expression in normal hematopoietic cells and chronic lymphocytic leukaemia: drug sensitivity or resistance? Leukemia 1993; 7: 1199-1203.
20. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994; 54: 4313-4320.
21. Panasci L, Henderson D, Torres-Garcia SJ, Skalski V, Caplan S, Hutchinson M. Transport, metabolism, and DNA interaction of melphalan in lymphocytes from patients with chronic lymphocytic leukemia. Cancer Res 1988; 48: 1972-1976.
22. Schisselbauer JC, Silber S, Papadopoulos E, Abrams K, LaCreat FP, Tew KD. Characterization of glutathione-S-transferase expression in lymphocytes from chronic lymphocytic leukemia patients. Cancer Res 1990; 50:3562-3568.
23. Marie JP, Simonin G, Legrand O, Delmer A, Faussat A-M, Lewis AD, Sikic BI, Zittoun R. Glutathione-S-transferase p, a, m and mdr1 mRNA expression in normal lymphocytes and chronic lymphocytic leukemia. Leukemia 1995; 9: 1742-1747.
24. Laemmli UK. Cleavage of structural proteins during the assembly of head of bacteriophage T4. Nature (Lond) 1970; 227: 680-685.
25. Drake FH, Zimmerman JP, McCabe FL, Barthus FH, Per SR, Sullivan DM, Ross WE, Mattern MR, Johnson RK, Crooke ST, Mirabelli CK. Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. J Biol Chem 1987; 262: 16739-16747.
26. Kaufmann SH, McLaughlin SJ, Kastan MB, Liu LF, Karp JE, Burke PJ. Topoisomerase II levels during granulocytic maturation in vitro and in vivo. Cancer Res 1991; 51: 3534-3543.
27. Habig WH, Pabst MJ, Jakoby WB. Glutathione-S-transferases: the first enzymatic step in mercapturic acid formation. J Biol Chem 1994; 239: 2379-2385.
28. Akerboom TP, Sies H. Assay of glutathione, glutathione disulfide, and glutathione mixed disulfides in biological samples. Meth Enzymol 1981; 77: 373-384.
29. Smith PK, Krohn RI, Hermanson CT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson B, Klenk DC. Measurement of protein using bicinchoninic acid. Anal Biochem 1985; 150: 76-85.
30. Foon KA, Gale RP. Staging and therapy of chronic lymphocytic leukemia. Sernin Hematol 1977; 24: 264-274.
31. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Crist W, Brodeur CM, Lieber M, Cossman J, Gotessman MM. Pastan I. Expression of the multidrug resistance gene in human cancers. J Natl Cancer Inst 1989; 81: 116-124.
32. Nooter K, Herweijer J. Multidrug resistance (mdr) genes in human cancer. Br J Cancer 1991; 63: 663-669.
33. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriarnycin-induced DNAdamage mediated by mammalian DNA topoisomerase II. Science 1983; 226: 466-468.
34. Yang L, Rowe TC, Liu LF. Identification of DNA topoisomerase II as an intracellular target of antitumor epipodophyllotoxins in simians virus 40-infected monkey cells. Cancer Res 1985; 45: 5872-5876.
35. Zunino F, Capranico G. DNA topoisomerase II as the primary target of antitumour anthracyclines. Anticancer Drug Desg 1990; 5: 307-317.
36. Drlika K, Franco RJ. Inhibitors of DNA topoisomerase. Biochemistry 1988; 27: 2253-2259.
37. Alton PA, Harris AL. The role of DNA topoisomerase II in drug resistance. Br J Haematol 1993; 85: 241-245.
38. Del Gliglio A, O'Brien S, Ford RJ, Manning J, Saya H, Keating M, Johnston D, Fisher Chamone D, Deisseroth AB. Proliferating cell nuclear antigen (PCNA) expression in chronic lymphocytic leukemia (CLL). Leuk Lymphoma 1993; 10: 265-271.
39. French Co-operative Group on Chronic Lymphocytic Leukemia. Is the CHOP regimen a good treatment for advanced CLL? Results from two randomized clinical trials. Leuk Lymphoma 1994; 13: 449-456.
40. Petrini M, Conte A, Caracciolo F, Sabbatini A, Grassi B, Ronca G. Reversing of chlorambucil resistance by ethacrynic acid in a B-CLL patient. Br J Haematol 1993; 85: 409-410.
41. Hall AG, Autzen P, Cattan AR, Malcolm AJ, Cole M, Kernahan J, Reid MM. Expression of μ class glutathione-S-transferase correlates with event-free survival in childhood acute lymphoblastic leukemia. Cancer Res 1994; 20: 5251-5255.